Character Biosciences, a Jersey City, N.J.-based precision medicine company improving drug development for polygenic diseases, raised $93M in Series B funding.
The round was led by aMoon and Luma Group, with additional participation from Bausch + Lomb and Jefferson Life Sciences, alongside existing investors Innovation Endeavors, Catalio Capital Management, S32, and KdT Ventures.
The company intends to use the funds to accelerate the advancement of its pipeline of precision therapies (lead candidates are CTX114 and CTX203) to treat degenerative eye diseases, starting with age-related macular degeneration (AMD).
Led by CEO Cheng Zhang, Character Biosciences is a precision medicine company developing targeted therapies for progressive polygenic diseases, starting with ophthalmology. By integrating genomics, deep clinical data, and AI-driven modeling, it identifies disease drivers to improve the success rate of drug development.
The company is advancing a pipeline focused on dry age-related macular degeneration (AMD) and primary open-angle glaucoma (POAG) to address significant unmet medical needs. CTX114, a best-in-class complement inhibitor, is designed to slow the progression of geographic atrophy in advanced dry AMD, while CTX203, a first-in-class lipid regulator, aims to prevent progression to advanced AMD.
FinSMEs
25/03/2025